ARCHIVES

Drug Development: FDA Grants Breakthrough Therapy Designation to CTL019 In ALL

This article is from The Cancer Letter archive.

Vol. 40 No. 28 | July 11, 2014

Download PDF Visit The Full Archive

Related Articles

Aranesp Improved Anemia In MDS In Phase II Trial

September 30, 2005

Bypass Budget Omits Needless Words: Faster Progress to Cost $421 Million More

March 29, 1996

Reports of SPOREs cut Premature, Broder Says, Wait for Peer Review

March 13, 1992

Lung Cancer Studies Described by DCT, VA

May 9, 1975

Summit Conference Reviews Leads In Leukemia, Lymphoma

January 8, 1982

Ambitious Radiation Oncology Research Plan Calls For “Concentrated Efforts” In Emerging Areas

June 12, 1987